Edition:
United States

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

5.02EUR
22 Jun 2017
Change (% chg)

-- (--)
Prev Close
€5.02
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
192,595
52-wk High
€5.78
52-wk Low
€3.05

MDXH.BR

Chart for MDXH.BR

About

MDxHealth SA is a Belgium-based multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis... (more)

Overall

Beta: 0.77
Market Cap(Mil.): €245.79
Shares Outstanding(Mil.): 49.95
Dividend: --
Yield (%): --

Financials

  MDXH.BR Industry Sector
P/E (TTM): -- 244.33 18.98
EPS (TTM): -0.26 -- --
ROI: -25.82 -7.97 -5.09
ROE: -27.16 -9.96 -4.32

BRIEF-MDxHealth and Queensland University of Technology collaborate on oral cancer liquid biopsy test

* REG-MDXHEALTH AND QUEENSLAND UNIVERSITY OF TECHNOLOGY COLLABORATE ON ORAL CANCER LIQUID BIOPSY TEST

Jun 19 2017

BRIEF-MdxHealth Q1 revenue growth of 128%, or $19.4 million

* Q1 SHARP REVENUE GROWTH OF 128%, OR $19.4 MILLION, COMPARED TO THE SAME PERIOD IN 2016

May 08 2017

BRIEF-MDxHealth and Maastricht University collaborate on (EPI)genetic cancer diagnostics

* Mdxhealth and maastricht university collaborate on next generation (EPI)genetic cancer diagnostics

May 05 2017

BRIEF-MDxhealth announces new contract with MediNcrease Health Plans regarding ConfirmMDx and SelectMDx

* Reg-MDxhealth announces new contract with MediNcrease Health Plans regarding ConfirmMDx and SelectMDx Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 02 2017

BRIEF-Mdxhealth and Exact Sciences sign collaboration agreement

* Mdxhealth and Exact Sciences sign collaboration agreement for collaboration in the growing field of epigenetics and molecular diagnostics

Apr 27 2017

BRIEF-Mdxhealth announces cost-effective results for its SelectMDx test for biopsy selection

* New study shows MDxHealth's SelectMDx test is cost-effective for biopsy selection

Apr 10 2017

BRIEF-Mdxhealth signs an exclusive licensing deal with Ghent University in Belgium

* Signed an exclusive licensing deal with Ghent University in Belgium

Apr 04 2017

BRIEF-MDxHealth identifies men at increased risk of prostate cancer recurrence

* Mdxhealth epigenetic biomarkers identify men at increased risk of prostate cancer recurrence

Mar 27 2017

BRIEF-MDxHealth signs agreement with Lab21 to make SelectMDX available in UK

* Signs agreement with Lab21 to make SelectMDX liquid biopsy test available in the United Kingdom Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 21 2017

BRIEF-MDxHealth: SelectMDx chosen by Michigan Medicine

* Reg-SelectMDx chosen by Michigan Medicine as pre-biopsy diagnostic tool in groundbreaking us prostate cancer risk clinic Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 08 2017

More From Around the Web

Earnings vs. Estimates